--- title: "Great Lakes Advisors LLC Takes Position in Biogen Inc. $BIIB" type: "News" locale: "en" url: "https://longbridge.com/en/news/296676602.md" description: "Great Lakes Advisors LLC acquired a new stake in Biogen Inc. (BIIB) during Q2, purchasing 9,477 shares valued at approximately $2.05 million. This move aligns with broader institutional interest, as other hedge funds like Empowered Funds and Focus Partners also increased their holdings. Meanwhile, Wall Street analysts maintain a 'Moderate Buy' consensus with an average price target of $227.07, despite recent rating adjustments from firms such as Wall Street Zen and Canaccord Genuity." datetime: "2026-08-22T08:02:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296676602.md) - [en](https://longbridge.com/en/news/296676602.md) - [zh-HK](https://longbridge.com/zh-HK/news/296676602.md) generator: "portal-rs" --- # Great Lakes Advisors LLC Takes Position in Biogen Inc. $BIIB Great Lakes Advisors LLC bought a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 9,477 shares of the biotechnology company's stock, valued at approximately $2,048,000. - MarketBeat Week in Review – 05/18 - 05/22 Several other hedge funds have also bought and sold shares of the stock. Empowered Funds LLC lifted its holdings in shares of Biogen by 64.9% in the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company's stock worth $965,000 after acquiring an additional 2,777 shares during the last quarter. Focus Partners Wealth raised its position in Biogen by 172.2% in the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company's stock worth $1,392,000 after purchasing an additional 6,436 shares during the period. Sivia Capital Partners LLC purchased a new stake in Biogen during the second quarter valued at about $216,000. Cerity Partners LLC increased its holdings in shares of Biogen by 15.3% in the second quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company's stock worth $5,847,000 after buying an additional 6,184 shares during the period. Finally, NewEdge Advisors LLC increased its holdings in shares of Biogen by 13.4% in the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company's stock worth $336,000 after buying an additional 316 shares during the period. 87.93% of the stock is currently owned by institutional investors. ## Wall Street Analysts Forecast Growth BIIB has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Biogen from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Canaccord Genuity Group boosted their price objective on shares of Biogen from $245.00 to $248.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. The Goldman Sachs Group upped their price objective on shares of Biogen from $231.00 to $238.00 and gave the company a "buy" rating in a research note on Friday, April 24th. Zacks Research upgraded shares of Biogen from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 28th. Finally, Royal Bank Of Canada reduced their price target on Biogen from $242.00 to $240.00 and set an "outperform" rating on the stock in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Biogen currently has an average rating of "Moderate Buy" and an average price target of $227.07. - Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish **Get Our Latest Report on BIIB** ## Biogen Trading Up 1.1% BIIB opened at $216.78 on Friday. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen Inc. has a 52 week low of $131.52 and a 52 week high of $222.15. The stock has a market cap of $32.03 billion, a PE ratio of 38.37, a PEG ratio of 6.68 and a beta of 0.17. The business has a 50 day moving average of $205.53 and a 200-day moving average of $194.48. - 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. The business had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The company's revenue was up 3.4% compared to the same quarter last year. During the same period last year, the business posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts predict that Biogen Inc. will post 12.39 earnings per share for the current fiscal year. ## Biogen Company Profile (Free Report) Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets. The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders. ## Read More - Five stocks we like better than Biogen - Blueprint for a Boom: SEC Clears the Crypto Runway - Ross Stores Just Flipped the Off-Price Retail Story After TJX's Marmaxx Miss - Advance Auto Parts Plunged, But Its Turnaround Is Still Working - Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Biogen Right Now? Before you consider Biogen, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list. While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [RY.US](https://longbridge.com/en/quote/RY.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) ## Related News & Research - [Is Wall Street Bullish or Bearish on Biogen Stock?](https://longbridge.com/en/news/296491913.md) - [Plato Investment Management Ltd Invests $1.49 Million in Biogen Inc. $BIIB](https://longbridge.com/en/news/296206286.md) - [Is Biogen (BIIB) Fully Priced After Earnings Raised Revenue But Cut Profit?](https://longbridge.com/en/news/295271686.md) - [Insight Guru says Health Care dominates mid-cap 52-week highs list, with 11 of 19 names at new peaks](https://longbridge.com/en/news/296464727.md) - [Biogen Inc. $BIIB Shares Sold by ADAR1 Capital Management LLC](https://longbridge.com/en/news/294165856.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**